These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15840903)

  • 1. Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts.
    Nakamura T; Matsumoto K; Mizuno S; Sawa Y; Matsuda H; Nakamura T
    Am J Physiol Heart Circ Physiol; 2005 May; 288(5):H2131-9. PubMed ID: 15840903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy.
    Taniyama Y; Morishita R; Aoki M; Hiraoka K; Yamasaki K; Hashiya N; Matsumoto K; Nakamura T; Kaneda Y; Ogihara T
    Hypertension; 2002 Jul; 40(1):47-53. PubMed ID: 12105137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters.
    Taniyama Y; Morishita R; Nakagami H; Moriguchi A; Sakonjo H; Shokei-Kim ; Matsumoto K; Nakamura T; Higaki J; Ogihara T
    Circulation; 2000 Jul; 102(2):246-52. PubMed ID: 10889138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic prostacyclin agonist, ONO1301, enhances endogenous myocardial repair in a hamster model of dilated cardiomyopathy: a promising regenerative therapy for the failing heart.
    Ishimaru K; Miyagawa S; Fukushima S; Saito A; Sakai Y; Ueno T; Sawa Y
    J Thorac Cardiovasc Surg; 2013 Dec; 146(6):1516-25. PubMed ID: 24229503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of dilated cardiomyopathy with electroporation of hepatocyte growth factor gene into skeletal muscle.
    Komamura K; Tatsumi R; Miyazaki J; Matsumoto K; Yamato E; Nakamura T; Shimizu Y; Nakatani T; Kitamura S; Tomoike H; Kitakaze M; Kangawa K; Miyatake K
    Hypertension; 2004 Sep; 44(3):365-71. PubMed ID: 15289469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of chronic AT(1) receptor blockade on cardiac Smad overexpression in hereditary cardiomyopathic hamsters.
    Dixon IM; Hao J; Reid NL; Roth JC
    Cardiovasc Res; 2000 May; 46(2):286-97. PubMed ID: 10773233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Klotho inhibits angiotensin II-induced cardiac hypertrophy, fibrosis, and dysfunction in mice through suppression of transforming growth factor-β1 signaling pathway.
    Ding J; Tang Q; Luo B; Zhang L; Lin L; Han L; Hao M; Li M; Yu L; Li M
    Eur J Pharmacol; 2019 Sep; 859():172549. PubMed ID: 31325434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene transfection of hepatocyte growth factor attenuates the progression of cardiac remodeling in the hypertrophied heart.
    Iwata K; Sawa Y; Kitagawa-Sakakida S; Kawaguchi N; Matsuura N; Nakamura T; Matsuda H
    J Thorac Cardiovasc Surg; 2005 Sep; 130(3):719-25. PubMed ID: 16153919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tissue factors contributing to cardiac hypertrophy in cardiomyopathic hamsters (BIO14.6): involvement of transforming growth factor-beta 1 and tissue renin-angiotensin system in the progression of cardiac hypertrophy].
    Sakata Y
    Hokkaido Igaku Zasshi; 1993 Jan; 68(1):18-28. PubMed ID: 8383086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular and molecular mechanisms of HGF/Met in the cardiovascular system.
    Gallo S; Sala V; Gatti S; Crepaldi T
    Clin Sci (Lond); 2015 Dec; 129(12):1173-93. PubMed ID: 26561593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with an adenoviral vector encoding hepatocyte growth factor mitigates established cardiac dysfunction in doxorubicin-induced cardiomyopathy.
    Esaki M; Takemura G; Kosai K; Takahashi T; Miyata S; Li L; Goto K; Maruyama R; Okada H; Kanamori H; Ogino A; Ushikoshi H; Minatoguchi S; Fujiwara T; Fujiwara H
    Am J Physiol Heart Circ Physiol; 2008 Feb; 294(2):H1048-57. PubMed ID: 18083897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient reciprocal change of renal hepatocyte growth factor and transforming growth factor-beta1 may relate to renal hypertrophy in rats with liver injury or unilateral nephrectomy.
    Tsau YK; Tsai IJ; Chen YM
    Pediatr Res; 2006 Apr; 59(4 Pt 1):494-9. PubMed ID: 16549518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II receptor blockade in Syrian hamster (T0-2) cardiomyopathy does not affect microscopic cardiac material properties: implications for mechanisms of tissue remodeling.
    Lanza GM; Scott MJ; Davison G; Hall CS; Christy DH; Miller JG; Wickline SA
    Cardiovasc Drugs Ther; 1997 Sep; 11(4):521-9. PubMed ID: 9358956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocyte growth factor attenuates transforming growth factor-β-angiotensin II crosstalk through inhibition of the PTEN/Akt pathway.
    Iekushi K; Taniyama Y; Kusunoki H; Azuma J; Sanada F; Okayama K; Koibuchi N; Iwabayashi M; Rakugi H; Morishita R
    Hypertension; 2011 Aug; 58(2):190-6. PubMed ID: 21670418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte growth factor counteracts transforming growth factor-beta1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice.
    Inoue T; Okada H; Kobayashi T; Watanabe Y; Kanno Y; Kopp JB; Nishida T; Takigawa M; Ueno M; Nakamura T; Suzuki H
    FASEB J; 2003 Feb; 17(2):268-70. PubMed ID: 12475893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galectin-3 deficiency ameliorates fibrosis and remodeling in dilated cardiomyopathy mice with enhanced Mst1 signaling.
    Nguyen MN; Ziemann M; Kiriazis H; Su Y; Thomas Z; Lu Q; Donner DG; Zhao WB; Rafehi H; Sadoshima J; McMullen JR; El-Osta A; Du XJ
    Am J Physiol Heart Circ Physiol; 2019 Jan; 316(1):H45-H60. PubMed ID: 30387702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,25-dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression.
    Li Y; Spataro BC; Yang J; Dai C; Liu Y
    Kidney Int; 2005 Oct; 68(4):1500-10. PubMed ID: 16164627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte growth factor prevents ventricular remodeling and dysfunction in mice via Akt pathway and angiogenesis.
    Wang Y; Ahmad N; Wani MA; Ashraf M
    J Mol Cell Cardiol; 2004 Nov; 37(5):1041-52. PubMed ID: 15522281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocyte growth factor suppresses transforming growth factor-beta-1 and type III collagen in human primary renal fibroblasts.
    Mou S; Wang Q; Shi B; Gu L; Ni Z
    Kaohsiung J Med Sci; 2009 Nov; 25(11):577-87. PubMed ID: 19858036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic prostacycline agonist, ONO-1301, ameliorates left ventricular dysfunction and cardiac fibrosis in cardiomyopathic hamsters.
    Hirata Y; Soeki T; Akaike M; Sakai Y; Igarashi T; Sata M
    Biomed Pharmacother; 2009 Dec; 63(10):781-6. PubMed ID: 19906506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.